[go: up one dir, main page]

NO307497B1 - Transdermalt terapeutisk system for administrering av galanthamin bestanddel - Google Patents

Transdermalt terapeutisk system for administrering av galanthamin bestanddel

Info

Publication number
NO307497B1
NO307497B1 NO952907A NO952907A NO307497B1 NO 307497 B1 NO307497 B1 NO 307497B1 NO 952907 A NO952907 A NO 952907A NO 952907 A NO952907 A NO 952907A NO 307497 B1 NO307497 B1 NO 307497B1
Authority
NO
Norway
Prior art keywords
galanthamine
pct
administration
transdermal therapeutic
therapeutic system
Prior art date
Application number
NO952907A
Other languages
English (en)
Norwegian (no)
Other versions
NO952907D0 (no
NO952907L (no
Inventor
Thomas Hille
Lothar Deurer
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of NO952907D0 publication Critical patent/NO952907D0/no
Publication of NO952907L publication Critical patent/NO952907L/no
Publication of NO307497B1 publication Critical patent/NO307497B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO952907A 1993-01-23 1995-07-21 Transdermalt terapeutisk system for administrering av galanthamin bestanddel NO307497B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4301783A DE4301783C1 (de) 1993-01-23 1993-01-23 Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
PCT/EP1994/000054 WO1994016707A1 (de) 1993-01-23 1994-01-10 Transdermales therapeutisches system mit galanthamin als wirksamen bestandteil

Publications (3)

Publication Number Publication Date
NO952907D0 NO952907D0 (no) 1995-07-21
NO952907L NO952907L (no) 1995-07-21
NO307497B1 true NO307497B1 (no) 2000-04-17

Family

ID=6478781

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952907A NO307497B1 (no) 1993-01-23 1995-07-21 Transdermalt terapeutisk system for administrering av galanthamin bestanddel

Country Status (26)

Country Link
US (1) US5700480A (pl)
EP (1) EP0680325B1 (pl)
JP (1) JPH08505632A (pl)
KR (1) KR100300477B1 (pl)
AT (1) ATE216240T1 (pl)
AU (1) AU679032B2 (pl)
CA (1) CA2153572C (pl)
CZ (1) CZ287053B6 (pl)
DE (2) DE4301783C1 (pl)
DK (1) DK0680325T3 (pl)
ES (1) ES2176234T3 (pl)
FI (1) FI113744B (pl)
HR (1) HRP940028B1 (pl)
HU (1) HU221165B1 (pl)
IL (1) IL108235A (pl)
MY (1) MY109926A (pl)
NO (1) NO307497B1 (pl)
NZ (1) NZ259857A (pl)
PH (1) PH31473A (pl)
PL (1) PL175083B1 (pl)
PT (1) PT680325E (pl)
SI (1) SI9400024A (pl)
SK (1) SK281339B6 (pl)
WO (1) WO1994016707A1 (pl)
YU (1) YU48607B (pl)
ZA (1) ZA94414B (pl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4429791C2 (de) * 1994-08-23 1997-04-24 Lohmann Therapie Syst Lts Medizinischer Haftkleber auf Basis von Polyacrylaten und dessen Verwendung
DE19509663A1 (de) 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
AU732803B2 (en) * 1996-01-17 2001-05-03 National Starch And Chemical Investment Holding Corporation Adhesives resistant to skin-penetration enhancers
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
ES2259746T3 (es) * 1996-07-15 2006-10-16 Alza Corporation Nuevas formulaciones para la administracion transdermica de fluoxetina.
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
DE19649534B4 (de) * 1996-11-29 2004-05-06 Lts Lohmann Therapie-Systeme Ag Verpackung aus Verbundpackstoff zum Verpacken von wirkstoffhaltigen Pflastern
DE19653605C2 (de) * 1996-12-20 2002-11-28 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US6193993B1 (en) * 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
PT1140105E (pt) * 1998-12-24 2004-03-31 Janssen Pharmaceutica Nv Composicao de galantamina de libertacao controlada
US6241998B1 (en) 1999-02-02 2001-06-05 Acutek International Dermatological patch
DE19906977C1 (de) * 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
US7052714B1 (en) * 1999-10-13 2006-05-30 Senju Pharmaceutical Co., Ltd Ophthalmic adhesive preparations for percutaneous adsorption
CA2393301A1 (en) * 1999-12-10 2001-06-21 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
KR20030072214A (ko) * 2000-05-26 2003-09-13 스미또모 세이야꾸 가부시키가이샤 완화된 부작용을 갖는 신규 재조합 아데노바이러스 벡터
FR2814368B1 (fr) * 2000-09-26 2004-05-07 Pf Medicament Preparation pharmaceutique a base d'oxans
DE10141652B4 (de) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
EP1763337A2 (en) * 2003-12-31 2007-03-21 Actavis Group HF Immediate, controlled and sustained release formulations of galanthamine
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
DE602006016441D1 (de) 2005-05-13 2010-10-07 Alza Corp Mehrlagiges arzneimittelausbringsystem mit sperre gegen reservoirmaterialfluss
EP1937226A2 (en) * 2005-09-23 2008-07-02 Alza Corporation Transdermal galantamine delivery system
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
DE102008059054A1 (de) 2008-11-26 2010-05-27 Otto Bock Pur Life Science Gmbh Polyurethanpflaster für die transdermale Applikation von Wirkstoffen und Verfahren zu dessen Herstellung
AU2011331511C1 (en) 2010-11-17 2018-01-18 Hexal Ag Transdermal therapeutic system comprising buprenorphine
KR101317158B1 (ko) 2011-02-18 2013-10-15 조선대학교산학협력단 갈란타민 또는 그의 염을 함유하는 경피흡수제제
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
JP6285820B2 (ja) * 2014-08-07 2018-02-28 久光製薬株式会社 ガランタミン含有経皮吸収製剤
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US20180008612A1 (en) * 2016-07-11 2018-01-11 Taho Pharmaceuticals Ltd. Transdermal delivery system containing galantamine or salts thereof
CA3155267A1 (en) 2019-11-06 2021-05-14 Thomas Hnat Topical formulations of cyclooxygenase inhibitors and their use
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1239318A (en) * 1983-04-27 1988-07-19 Hans R. Hoffmann Pharmaceutical product preferably in medical bandage form and process for producing them
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE3843239C1 (pl) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
JP3291730B2 (ja) * 1991-05-14 2002-06-10 エルニア スノラソン 疲労症候群の治療

Also Published As

Publication number Publication date
HU221165B1 (en) 2002-08-28
HUT72643A (en) 1996-05-28
HRP940028B1 (en) 2000-02-29
SI9400024A (en) 1994-09-30
IL108235A0 (en) 1994-04-12
CZ287053B6 (en) 2000-08-16
FI113744B (fi) 2004-06-15
PH31473A (en) 1998-11-03
DE4301783C1 (de) 1994-02-03
HU9501928D0 (en) 1995-09-28
NO952907D0 (no) 1995-07-21
PL175083B1 (pl) 1998-10-30
CZ184295A3 (en) 1996-01-17
JPH08505632A (ja) 1996-06-18
CA2153572A1 (en) 1994-08-04
AU679032B2 (en) 1997-06-19
MY109926A (en) 1997-09-30
EP0680325B1 (de) 2002-04-17
AU5881794A (en) 1994-08-15
NZ259857A (en) 1996-03-26
KR100300477B1 (ko) 2001-10-22
NO952907L (no) 1995-07-21
PT680325E (pt) 2002-09-30
US5700480A (en) 1997-12-23
FI953533L (fi) 1995-07-21
YU48607B (sh) 1998-12-23
KR960700060A (ko) 1996-01-19
SK88995A3 (en) 1996-05-08
EP0680325A1 (de) 1995-11-08
YU2694A (sh) 1996-10-18
PL309603A1 (en) 1995-10-30
SK281339B6 (sk) 2001-02-12
WO1994016707A1 (de) 1994-08-04
HRP940028A2 (en) 1996-06-30
DK0680325T3 (da) 2002-08-05
IL108235A (en) 1996-10-31
DE59410103D1 (de) 2002-05-23
ATE216240T1 (de) 2002-05-15
FI953533A0 (fi) 1995-07-21
CA2153572C (en) 2006-01-03
ZA94414B (en) 1994-08-31
ES2176234T3 (es) 2002-12-01

Similar Documents

Publication Publication Date Title
NO307497B1 (no) Transdermalt terapeutisk system for administrering av galanthamin bestanddel
GB9211033D0 (en) The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
BR0109893A (pt) Preparação farmacêutica de lerisetron na forma de um sistema terapêutico transdêrmico, uso da preparação, uso da substância ativa lerisetron e método para administrar a substância ativa lerisetron a um paciente
NO952908D0 (no) Nitroglycerolholdig plaster, fremgangsmåte for fremstilling, samt anvendelse av plasteret
LV10749A (lv) Transdermala terapeitiska sistema fizostigmina uzliksanai uz adas un tas izgatavosanas panemiens

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees